<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20240104060613N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2024-02-02</date_registration>
      <primary_sponsor>Zahedan University of Medical Sciences</primary_sponsor>
      <public_title>Investigating the Effect of High-Flow Oxygen Administration on the Weaning Outcomes of Patients from Mechanical Ventilation After Coronary Artery Bypass Graft Surgery</public_title>
      <acronym></acronym>
      <scientific_title>Investigating the Effect of High-Flow Oxygen Administration on the Weaning Outcomes of Patients from Mechanical Ventilation After Coronary Artery Bypass Graft Surgery</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2024-01-16</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>80</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/74965</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Not blinded, Placebo: Not used, Assignment: Parallel, Purpose: Prevention, Randomization description: Patients undergoing mechanical ventilation who met the inclusion criteria were selected using a convenience sampling method and then assigned to two intervention and control groups using a simple randomization method using blue and red colored cards. A total of 80 cards (40 blue cards and 40 red cards) will be prepared in an envelope. The blue cards will be designated for the intervention group, while the red cards will be designated for the control group. Upon the admission of each patient to the intensive care unit, one card will be drawn from the envelope. If a blue card is drawn, the patient will be assigned to the intervention group; if a red card is drawn, the patient will be assigned to the control group. This process will continue until the eightieth card is drawn from the envelope.</study_design>
      <phase>N/A</phase>
      <hc_freetext>Coronary Artery Disease.</hc_freetext>
      <i_freetext>Intervention 1: Intervention Group: In the intervention group, after extubation, high-flow oxygen therapy will be administered using a high-flow oxygen delivery device through a nasal cannula for up to 12 hours. Select an appropriately sized nasal cannula to prevent nasal discomfort. Patients' nostrils are lubricated with petroleum jelly to reduce the risk of epistaxis and dry mucous membranes. The initial oxygen flow rate will be set at 10 liters per minute, and if patients are comfortable, the flow rate will be increased by 5 liters per minute. The temperature of the delivered oxygen will be set at 37 degrees Celsius, and if the patient experiences discomfort, the oxygen temperature will be reduced by one degree down to a minimum of 35 degrees Celsius.The prescribed oxygen flow will be adjusted based on the patients' blood oxygen saturation levels, decreasing or increasing by 5 liters per minute to maintain arterial oxygen saturation levels measured by a pulse oximeter above 90 percent. After 12 hours, high-flow oxygen therapy will be stopped, and if patients still require oxygen administration, oxygen therapy will continue with a simple face mask at a flow rate of 5 to 10 liters per minute based on the patients' needs. Intervention 2: Control Group: In the control group, after extubation, patients will receive oxygen via nasal cannula at 6-10 L/min, titrated to maintain oxygen saturation above 90%.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Yes - There is a plan to make this available</results_IPD_plan>
      <results_IPD_description>What will be shared:
After completing the study, data extraction and analysis will be published as an article.

When:
After completing the study, data extraction and analysis will be published as an article.

To whom:
After completing the study, data extraction and analysis will be published as an article.

Conditions:
After completing the study, data extraction and analysis will be published as an article.

Where to obtain:
After completing the study, data extraction and analysis will be published as an article.

How to obtain:
After completing the study, data extraction and analysis will be published as an article.

Comments:
</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Abdolrab Dorazehi</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>No.13, Infront of Azadi 50, South Azadi Blvd, Iranshahr Town</address>
        <city>Iranshahr</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>9914943749</zip>
        <telephone>+98 54 3722 6364</telephone>
        <email>abdoldora1990@gmail.com</email>
        <affiliation>Zahedan University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Abdolrab Dorazehi</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>No.13, Infront of Azadi 50, South Azadi Blvd, Iranshahr Town</address>
        <city>Iranshahr</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>9914943749</zip>
        <telephone>+98 54 3722 6364</telephone>
        <email>abdoldora1990@gmail.com</email>
        <affiliation>Zahedan University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Age ≥18 years old
Mechanical ventilation for a minimum of 12 hours and a maximum of 48 hours
No significant bleeding occurred post-surgery (defined as bleeding from the chest tube exceeding 200 ml every hour in the first three hours post-operation).</inclusion_criteria>
      <agemin>18 years</agemin>
      <agemax>no limit</agemax>
      <gender>Both</gender>
      <exclusion_criteria>Severe pneumonia and acute respiratory failure during the study
Persistent ventricular tachycardia requiring therapeutic intervention
Unplanned extubation by the patient
Need for tracheostomy placement</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>I25.1</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Atherosclerotic heart disease of native coronary artery</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Prevention</i_code>
      <i_code>Prevention</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention Group: In the intervention group, after extubation, high-flow oxygen therapy will be administered using a high-flow oxygen delivery device through a nasal cannula for up to 12 hours. Select an appropriately sized nasal cannula to prevent nasal discomfort. Patients' nostrils are lubricated with petroleum jelly to reduce the risk of epistaxis and dry mucous membranes. The initial oxygen flow rate will be set at 10 liters per minute, and if patients are comfortable, the flow rate will be increased by 5 liters per minute. The temperature of the delivered oxygen will be set at 37 degrees Celsius, and if the patient experiences discomfort, the oxygen temperature will be reduced by one degree down to a minimum of 35 degrees Celsius.The prescribed oxygen flow will be adjusted based on the patients' blood oxygen saturation levels, decreasing or increasing by 5 liters per minute to maintain arterial oxygen saturation levels measured by a pulse oximeter above 90 percent. After 12 hours, high-flow oxygen therapy will be stopped, and if patients still require oxygen administration, oxygen therapy will continue with a simple face mask at a flow rate of 5 to 10 liters per minute based on the patients' needs.</i_keyword>
      <i_keyword>Control Group: In the control group, after extubation, patients will receive oxygen via nasal cannula at 6-10 L/min, titrated to maintain oxygen saturation above 90%.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Reintubation rate. Timepoint: Forty-eight hours after weaning patients from the ventilator. Method of measurement: Extubation intolerance leading to respiratory failure and reintubation within 48 hours of weaning.</prim_outcome>
      <prim_outcome>Arterial blood carbon dioxide pressure (PaCO2). Timepoint: Measurements will be recorded immediately before extubation, and then 6 and 12 hours post-extubation. Method of measurement: It will be measured through arterial blood gas analysis.</prim_outcome>
      <prim_outcome>Arterial oxygen pressure (PaO2). Timepoint: Measurements will be recorded immediately before extubation, and then 6 and 12 hours post-extubation. Method of measurement: It will be measured through arterial blood gas analysis.</prim_outcome>
      <prim_outcome>Arterial blood bicarbonate (HCO3). Timepoint: Measurements will be recorded immediately before extubation, and then 6 and 12 hours post-extubation. Method of measurement: It will be measured through arterial blood gas analysis.</prim_outcome>
      <prim_outcome>Arterial oxygen saturation percentage (SPO2). Timepoint: Measurements will be recorded immediately before extubation, and then 6 and 12 hours post-extubation. Method of measurement: It is measured through pulse oximeter and arterial blood gas analysis.</prim_outcome>
      <prim_outcome>PaO2/FiO2 ratio. Timepoint: Measurements will be recorded immediately before extubation, and then 6 and 12 hours post-extubation. Method of measurement: It is calculated by dividing the arterial blood oxygen pressure measured by arterial blood gas analysis by the percentage fractional inspired oxygen (PaO2/FiO2).</prim_outcome>
      <prim_outcome>Heart Rate (HR). Timepoint: Measurements will be recorded immediately before extubation, and then 6 and 12 hours post-extubation. Method of measurement: Heart rate is measured via bedside monitoring.</prim_outcome>
      <prim_outcome>Mean arterial pressure (MAP). Timepoint: Measurements will be recorded immediately before extubation, and then 6 and 12 hours post-extubation. Method of measurement: Mean arterial pressure (MAP) is measured via patient bedside monitoring.</prim_outcome>
      <prim_outcome>Systolic blood pressure (SBP). Timepoint: Measurements will be recorded immediately before extubation, and then 6 and 12 hours post-extubation. Method of measurement: Systolic blood pressure is measured via patient bedside monitoring.</prim_outcome>
      <prim_outcome>Diastolic blood pressure (DBP). Timepoint: Measurements will be recorded immediately before extubation, and then 6 and 12 hours post-extubation. Method of measurement: Diastolic blood pressure is measured via patient bedside monitoring.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>ICU long stay (ILS). Timepoint: The duration of stay in the intensive care unit (ICU) for open-heart surgery patients is calculated from the day of admission to the day of discharge. Method of measurement: The number of days admitted to the intensive care unit of patients after coronary artery bypass graft surgery is calculated and recorded from the day of admission to the open heart intensive care unit until discharge from this unit.</sec_outcome>
      <sec_outcome>Hospital long stay (HLS). Timepoint: From the day of coronary artery bypass surgery until the day of discharge from the hospital. Method of measurement: The number of days after coronary artery bypass graft surgery will be calculated and recorded from the day of admission to the intensive care unit until the day of discharge from the hospital.</sec_outcome>
      <sec_outcome>Mortality. Timepoint: The mortality rate of patients from the time of admission to discharge from the hospital will be recorded in two groups of intervention and control. Method of measurement: The mortality rate of patients will be recorded until they are discharged from the hospital.</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Zahedan University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2023-12-24</approval_date>
        <contact_name>Ethics committee of Zahedan University of Medical Sciences</contact_name>
        <contact_address>Sistan and Baluchestan Province, Zahedan, Emam Hosain Blvd Integrating the campus of the University of Medical Sciences Zahedan Sistan-va-Balouchestan Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
